January 14th, 2013
Advisory Panel Recommends Approval of Diabetes Drug Canagliflozin
Christine Sadlowski, MS
An advisory committee to the FDA recommended approving canagliflozin, a new type of drug for type 2 diabetes, late last week, the New York Times reports. The once-daily oral drug is a selective sodium glucose co-transporter 2 inhibitor. It prevents reabsorption of glucose by the kidney, thereby increasing glucose excretion in the urine and reducing blood […]
NEJM Journal Watch — Recent Cardiology Articles- Cardiovascular Outcomes of Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long Is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction